This tender seeks qualified manufacturers to produce PSMA-11, a radiopharmaceutical used in targeted cancer therapy. Bidders must demonstrate compliance with Good Manufacturing Practices (GMP) and relevant regulatory standards.
The South African Nuclear Energy Corporation Limited is inviting tenders for the manufacturing of PSMA-11, a critical radiopharmaceutical utilized in the treatment of prostate cancer. This tender emphasizes the need for adherence to Good Manufacturing Practices (GMP), ensuring that all products meet stringent quality and safety standards. Interested parties must provide evidence of their capability to produce PSMA-11 in compliance with applicable regulatory requirements.
The scope of this tender includes the full manufacturing process of PSMA-11, from sourcing raw materials to final product packaging. Bidders should outline their production capabilities, quality control measures, and experience in handling similar pharmaceutical products. The successful bidder will play a vital role in enhancing cancer treatment options within South Africa, contributing to improved patient outcomes and healthcare advancements.
This opportunity is particularly suited for established pharmaceutical manufacturers with a proven track record in GMP compliance and experience in producing radiopharmaceuticals. The tender will remain open for submissions until October 10, 2025, and interested parties are encouraged to review the supporting documents for detailed requirements and specifications.
This tender is suitable for pharmaceutical companies specializing in radiopharmaceutical production, particularly those with GMP certification and experience in cancer treatment products.
•••••• •••• ••••••• ••••• •••••• •••••• •••••• ••••.
Get full access to this tender, including documents, location, and contact details.